Drug Profile
HWH 340
Alternative Names: HWH340Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Hubei Biological Medicine Industrial Technology Institute
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in China (PO, Tablet)
- 21 Apr 2018 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
- 05 Mar 2018 Phase-I clinical trials in Solid tumours (Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in China (PO) (NCT03415659)